WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...
Despite these positive outcomes, EyePoint's stock experienced a sharp decline. Cantor Fitzgerald analyst Jennifer Kim commented on the market reaction, stating, "There's nothing here that makes us ...
Investing.com -- Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ: EYPT) fell 21% today, diverging from the company's recent announcement of positive results from the Phase 2 VERONA clinical ...
Researchers from the University of Glasgow, RMIT University, and Princeton University created a new diamond transistor for ...
Chinese researchers are tackling dendrite formation in zinc-ion batteries with the development of an anisotropic and ...
A company that emerged from the marine engineering sector holds the secret to the ultra-luxury brand’s remarkable material ...
The Union government has informed the Bombay High Court that plastic flowers are not included in the list of banned ...
Just a short distance outside of Fort Collins on the Colorado State University Foothills Campus sits one of the most powerful lasers in the world. Directed by professors and run by graduate students ...
The ship wasn’t damaged, and its crew is safe, officials said. Freighters in the Great Lakes often encounter surface ice in the winter but sometimes run into ice that is too hard or thick to break ...
Every manufacturer, and brand owner of plastic carry bags and packaging in India will have to provide all its details ...
Installation of plasma deposition tool at chip research manufacturing line is part of $10 million in upgrades to R&D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback